Treatment of heart failure in long-term dialysis patients: A reappraisal

American Journal of Kidney Diseases

Volumn 57, Issue 5, 2011, Pages 760-772

  Wang, Angela Yee Moon ^a   Sanderson, John E ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

dialysis; end stage renal disease (ESRD); Heart failure; therapeutics; treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCITRIOL; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ERYTHROPOIETIN; ETANERCEPT; FOSINOPRIL; INFLIXIMAB; IRON; ISTAROXIME; LOOP DIURETIC AGENT; NORADRENALIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMAPATRILAT; PLACEBO; SPIRONOLACTONE; TOLVAPTAN;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPETITIVE INHIBITION; DEVICE THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EARLY INTERVENTION; EXTRACORPOREAL ULTRAFILTRATION; HEART DEATH; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IRON THERAPY; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEGATIVE FEEDBACK; NONHUMAN; NORADRENALIN BLOOD LEVEL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL ULTRAFILTRATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SALT INTAKE; SODIUM BALANCE; SODIUM RESTRICTION; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE;

ANIMALS; CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954601364     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.01.014     Document Type: Review

References (123)

1. A.J. Collins, R.N. Foley, and C. Herzog United States Renal Data System 2008 Annual Data Report Am J Kidney Dis 53 1 suppl 1 2009 S1 S374
2. A.S. Levey, J.A. Beto, and B.E. Coronado Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 5 1998 853 906 (Pubitemid 28516321)
3. A.K. Cheung, M.J. Sarnak, and G. Yan Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study Kidney Int 65 6 2004 2380 2389 (Pubitemid 38670024)
4. A.G. Stack, and W.E. Bloembergen A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients Am J Kidney Dis 38 5 2001 992 1000 (Pubitemid 33022177)
5. A.Y. Wang, C.W. Lam, and C.M. Yu Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis Kidney Int 70 3 2006 444 452 (Pubitemid 44141570)
6. J.D. Harnett, R.N. Foley, G.M. Kent, P.E. Barre, D. Murray, and P.S. Parfrey Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors Kidney Int 47 3 1995 884 890
7. F.C. Trespalacios, A.J. Taylor, L.Y. Agodoa, G.L. Bakris, and K.C. Abbott Heart failure as a cause for hospitalization in chronic dialysis patients Am J Kidney Dis 41 6 2003 1267 1277 (Pubitemid 36637983)
8. J.M. Soucie, and W.M. McClellan Early death in dialysis patients: risk factors and impact on incidence and mortality rates J Am Soc Nephrol 7 10 1996 2169 2175 (Pubitemid 27468246)
9. P.S. Parfrey, S.M. Griffiths, and J.D. Harnett Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease, and ischemic heart disease in dialysis patients Am J Nephrol 10 3 1990 213 221 (Pubitemid 20305000)
10. P. Roy, J. Bouchard, R. Amyot, and F. Madore Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients Am J Kidney Dis 48 4 2006 645 651 (Pubitemid 44402833)
11. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients Am J Kidney Dis 45 4 suppl 3 2005 S1 S153
12. E. Ritz, R. Dikow, M. Adamzcak, and M. Zeier Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients Semin Dial 15 3 2002 135 140 (Pubitemid 41765923)
13. M. Ozkahya, E. Ok, and M. Cirit Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs Nephrol Dial Transplant 13 6 1998 1489 1493 (Pubitemid 28254325)
14. A.I. Gunal, I. Karaca, B. Aygen, M. Yavuzkir, A. Dogukan, and H. Celiker Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study J Int Med Res 32 1 2004 70 77 (Pubitemid 38159234)
15. R. Agarwal, and M.R. Weir Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients Clin J Am Soc Nephrol 5 7 2010 1255 1260
16. M. Jessup, W.T. Abraham, and D.E. Casey 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 14 2009 1977 2016
17. L.C. van Campen, F.C. Visser, and C.A. Visser Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature J Cardiovasc Pharmacol 32 suppl 1 1998 S31 S35
18. M. Packer Effects of beta-adrenergic blockade on survival of patients with chronic heart failure Am J Cardiol 80 suppl 11A 1997 46L 54L (Pubitemid 27528447)
19. M. Packer, M.R. Bristow, and J.N. Cohn The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 21 1996 1349 1355 (Pubitemid 26152713)
20. P.A. Heidenreich, T.T. Lee, and B.M. Massie Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials J Am Coll Cardiol 30 1 1997 27 34 (Pubitemid 27357123)
21. G. Ligtenberg Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension Neth J Med 55 1 1999 13 18 (Pubitemid 29313190)
22. D. Bernardi, L. Bernini, G. Cini, S. Ghione, and I. Bonechi Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients Am Heart J 109 3, pt 1 1985 539 545 (Pubitemid 16256706)
23. C. Zoccali, F. Mallamaci, and S. Parlongo Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease Circulation 105 11 2002 1354 1359 (Pubitemid 34260428)
24. J.N. Cohn, T.B. Levine, and M.T. Olivari Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 13 1984 819 823 (Pubitemid 14035089)
25. R.N. Foley, C.A. Herzog, and A.J. Collins Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study Kidney Int 62 5 2002 1784 1790 (Pubitemid 35286287)
26. J.B. Wetmore, and T.I. Shireman The ABCs of cardioprotection in dialysis patients: a systematic review Am J Kidney Dis 53 3 2009 457 466
27. B. Kestenbaum, D.L. Gillen, D.J. Sherrard, S. Seliger, A. Ball, and C. Stehman-Breen Calcium channel blocker use and mortality among patients with end-stage renal disease Kidney Int 61 6 2002 2157 2164 (Pubitemid 34539333)
28. K.C. Abbott, F.C. Trespalacios, L.Y. Agodoa, A.J. Taylor, and G.L. Bakris Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality Arch Intern Med 164 22 2004 2465 2471 (Pubitemid 39628074)
29. A.K. Berger, S. Duval, and H.M. Krumholz Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction J Am Coll Cardiol 42 2 2003 201 208 (Pubitemid 36851405)
30. A.A. Lopes, J.L. Bragg-Gresham, and S.P. Ramirez Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS Nephrol Dial Transplant 24 9 2009 2809 2816
31. G. Cice, L. Ferrara, and A. Di Benedetto Dilated cardiomyopathy in dialysis patientsbeneficial effects of carvedilol: a double-blind, placebo-controlled trial J Am Coll Cardiol 37 2 2001 407 411
32. G. Cice, L. Ferrara, and A. D'Andrea Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial J Am Coll Cardiol 41 9 2003 1438 1444 (Pubitemid 36543357)
33. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure The SOLVD Investigators N Engl J Med 325 5 1991 293 302
34. M.A. Konstam, M.W. Kronenberg, and M.F. Rousseau Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction SOLVD (Studies of Left Ventricular Dysfunction) Investigators Circulation 88 5, pt 1 1993 2277 2283 (Pubitemid 23326108)
35. M.D. Flather, S. Yusuf, and L. Kober Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet 355 9215 2000 1575 1581 (Pubitemid 30240501)
36. S. Yusuf, R. Garg, and D. McConachie Effect of angiotensin-converting enzyme inhibitors in left ventricular dysfunction: results of the studies of left ventricular dysfunction in the context of other similar trials J Cardiovasc Pharmacol 22 suppl 9 1993 S28 S35
37. J.B. Young, M.E. Dunlap, and M.A. Pfeffer Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials Circulation 110 17 2004 2618 2626 (Pubitemid 39456438)
38. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 3 2000 145 153
39. R. Latini, G. Tognoni, and A.P. Maggioni Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients Angiotensin- converting Enzyme Inhibitor Myocardial Infarction Collaborative Group J Am Coll Cardiol 35 7 2000 1801 1807 (Pubitemid 30342859)
40. A. Ichihara, M. Hayashi, and Y. Kaneshiro Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients Am J Kidney Dis 45 5 2005 866 874 (Pubitemid 43181046)
41. J. Blacher, A.P. Guerin, B. Pannier, S.J. Marchais, M.E. Safar, and G.M. London Impact of aortic stiffness on survival in end-stage renal disease Circulation 99 18 1999 2434 2439 (Pubitemid 29218240)
42. G.M. London, B. Pannier, A.P. Guerin, S.J. Marchais, M.E. Safar, and J.L. Cuche Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease Comparative effects of ACE inhibition and calcium channel blockade Circulation 90 6 1994 2786 2796
43. G. Cannella, E. Paoletti, R. Delfino, G. Peloso, D. Rolla, and S. Molinari Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects Am J Kidney Dis 30 5 1997 659 664 (Pubitemid 27465360)
44. A.P. Guerin, J. Blacher, B. Pannier, S.J. Marchais, M.E. Safar, and G.M. London Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure Circulation 103 7 2001 987 992 (Pubitemid 32183805)
45. G. Ligtenberg, P.J. Blankestijn, and P.L. Oey Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure N Engl J Med 340 17 1999 1321 1328 (Pubitemid 29196594)
46. K. Amann, K. Tyralla, and M.L. Gross Cardiomyocyte loss in experimental renal failure: prevention by ramipril Kidney Int 63 5 2003 1708 1713 (Pubitemid 36513316)
47. K. Amann, P. Gassmann, and M. Buzello Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats Kidney Int 58 1 2000 153 161 (Pubitemid 30429860)
48. F. Zannad, M. Kessler, and P. Lehert Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 7 2006 1318 1324 (Pubitemid 44435184)
49. A. Takahashi, H. Takase, and T. Toriyama Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysisa randomized study Nephrol Dial Transplant 21 9 2006 2507 2512 (Pubitemid 44644524)
50. G. Cice, A. Di Benedetto, and S. D'Isa Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial J Am Coll Cardiol 56 21 2010 1701 1708
51. S. Efrati, R. Zaidenstein, and V. Dishy ACE inhibitors and survival of hemodialysis patients Am J Kidney Dis 40 5 2002 1023 1029 (Pubitemid 35265483)
52. P.A. McCullough, K.R. Sandberg, J. Yee, and M.P. Hudson Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease J Renin Angiotensin Aldosterone Syst 3 3 2002 188 191 (Pubitemid 35345618)
53. W.C. Winkelmayer, D.M. Charytan, R. Levin, and J. Avorn Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction Am J Kidney Dis 47 2 2006 301 308 (Pubitemid 43121333)
54. W. Fang, D.G. Oreopoulos, and J.M. Bargman Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol Dial Transplant 23 11 2008 3704 3710
55. K.T. Weber Aldosterone in congestive heart failure N Engl J Med 345 23 2001 1689 1697 (Pubitemid 33126826)
56. M. Briet, and E.L. Schiffrin Aldosterone: effects on the kidney and cardiovascular system Nat Rev Nephrol 6 5 2010 261 273
57. J. Staessen, P. Lijnen, R. Fagard, L.J. Verschueren, and A. Amery Rise in plasma concentration of aldosterone during long-term angiotensin II suppression J Endocrinol 91 3 1981 457 465 (Pubitemid 12203819)
58. C. Borghi, S. Boschi, E. Ambrosioni, G. Melandri, A. Branzi, and B. Magnani Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors J Clin Pharmacol 33 1 1993 40 45 (Pubitemid 23067505)
59. U.P. Jorde, T. Vittorio, S.D. Katz, P.C. Colombo, F. Latif, and T.H. Le Jemtel Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure Circulation 106 9 2002 1055 1057 (Pubitemid 34970843)
60. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 10 1999 709 717 (Pubitemid 29407370)
61. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 14 2003 1309 1321 (Pubitemid 36384098)
62. B. Pitt, H. White, and J. Nicolau Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure J Am Coll Cardiol 46 3 2005 425 431 (Pubitemid 41040281)
63. N.C. Edwards, R.P. Steeds, P.M. Stewart, C.J. Ferro, and J.N. Townend Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 6 2009 505 512
64. G.J. Mak, M.T. Ledwidge, and C.J. Watson Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone J Am Coll Cardiol 54 18 2009 1674 1682
65. S. Hussain, D.E. Dreyfus, R.J. Marcus, R.W. Biederman, and R.L. McGill Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 18 11 2003 2364 2368 (Pubitemid 37336826)
66. P. Saudan, F. Mach, and T. Perneger Safety of low-dose spironolactone administration in chronic haemodialysis patients Nephrol Dial Transplant 18 11 2003 2359 2363 (Pubitemid 37336825)
67. E. Gross, M. Rothstein, S. Dombek, and H.I. Juknis Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients Am J Kidney Dis 46 1 2005 94 101 (Pubitemid 40848437)
68. J.J. McMurray, B. Pitt, and R. Latini Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 1 2008 17 24
69. P.S. Sever, A.H. Gradman, and M. Azizi Managing cardiovascular and renal risk: the potential of direct renin inhibition J Renin Angiotensin Aldosterone Syst 10 2 2009 65 76
70. I. Anand, J.J. McMurray, and J. Whitmore Anemia and its relationship to clinical outcome in heart failure Circulation 110 2 2004 149 154 (Pubitemid 38924582)
71. J.A. Ezekowitz, F.A. McAlister, and P.W. Armstrong Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure Circulation 107 2 2003 223 225 (Pubitemid 36135214)
72. A.S. Go, J. Yang, and L.M. Ackerson Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation 113 23 2006 2713 2723 (Pubitemid 43947989)
73. D.S. Silverberg, D. Wexler, and M. Blum The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations J Am Coll Cardiol 35 7 2000 1737 1744 (Pubitemid 30342851)
74. P. van der Meer, H.F. Groenveld, J.L. Januzzi Jr, and D.J. van Veldhuisen Erythropoietin treatment in patients with chronic heart failure: a meta-analysis Heart 95 16 2009 1309 1314
75. A. Levin, C.R. Thompson, and J. Ethier Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 34 1 1999 125 134 (Pubitemid 29318806)
76. R.N. Foley, P.S. Parfrey, and J. Morgan Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy Kidney Int 58 3 2000 1325 1335
77. A. Besarab, W.K. Bolton, and J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 9 1998 584 590 (Pubitemid 28385655)
78. M. Penicka, J. Bartunek, and O. Lang Severe left ventricular dyssynchrony is associated with poor prognosis in patients with moderate systolic heart failure undergoing coronary artery bypass grafting J Am Coll Cardiol 50 14 2007 1315 1323 (Pubitemid 47454688)
79. W.T. Abraham, W.G. Fisher, and A.L. Smith Cardiac resynchronization in chronic heart failure N Engl J Med 346 24 2002 1845 1853 (Pubitemid 34603028)
80. A. Phrommintikul, S.J. Haas, M. Elsik, and H. Krum Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis Lancet 369 9559 2007 381 388 (Pubitemid 46188479)
81. S.A. Timmer, K. De Boer, P. Knaapen, M.J. Gotte, and A.C. Van Rossum The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 15 4 2009 353 361
82. G.B. Bleeker, J.J. Bax, P. Steendijk, M.J. Schalij, and E.E. van der Wall Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment Nat Clin Pract Cardiovasc Med 3 4 2006 213 219
83. S.H. Shin, C.L. Hung, and H. Uno Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both Circulation 121 9 2010 1096 1103
84. M.R. Bristow, L.A. Saxon, and J. Boehmer Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 21 2004 2140 2150
85. J.G. Cleland, J.C. Daubert, and E. Erdmann The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 15 2005 1539 1549 (Pubitemid 40517094)
86. F.A. McAlister, J.A. Ezekowitz, and N. Wiebe Systematic review: cardiac resynchronization in patients with symptomatic heart failure Ann Intern Med 141 5 2004 381 390
87. B. Charra, J. Bergstrom, and B.H. Scribner Blood pressure control in dialysis patients: importance of the lag phenomenon Am J Kidney Dis 32 5 1998 720 724 (Pubitemid 28516300)
88. M.R. Costanzo, M.E. Guglin, and M.T. Saltzberg Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 6 2007 675 683 (Pubitemid 46205043)
89. J. Ly, and C.T. Chan Impact of augmenting dialysis frequency and duration on cardiovascular function ASAIO J 52 6 2006 e11 e14
90. J.O. Burton, H.J. Jefferies, N.M. Selby, and C.W. McIntyre Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function Clin J Am Soc Nephrol 4 12 2009 1925 1931
91. N.M. Selby, S.H. Lambie, P.G. Camici, C.S. Baker, and C.W. McIntyre Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis Am J Kidney Dis 47 5 2006 830 841
92. N.M. Selby, J.O. Burton, L.J. Chesterton, and C.W. McIntyre Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate Clin J Am Soc Nephrol 1 6 2006 1216 1225
93. C.T. Chan, P.J. Harvey, P. Picton, A. Pierratos, J.A. Miller, and J.S. Floras Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis Hypertension 42 5 2003 925 931 (Pubitemid 37413732)
94. C.T. Chan, J.S. Floras, J.A. Miller, R.M. Richardson, and A. Pierratos Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis Kidney Int 61 6 2002 2235 2239 (Pubitemid 34539341)
95. C. Chan, J.S. Floras, J.A. Miller, and A. Pierratos Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure Nephrol Dial Transplant 17 8 2002 1518 1521
96. B.F. Culleton, M. Walsh, and S.W. Klarenbach Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial JAMA 298 11 2007 1291 1299 (Pubitemid 47443343)
97. K.L. Johansen, R. Zhang, and Y. Huang Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study Kidney Int 76 9 2009 984 990
98. G.M. Chertow, N.W. Levin, and G.J. Beck In-center hemodialysis six times per week versus three times per week N Engl J Med 363 24 2010 2287 2300
99. A.H. Tzamaloukas, M.C. Saddler, and G.H. Murata Symptomatic fluid retention in patients on continuous peritoneal dialysis J Am Soc Nephrol 6 2 1995 198 206
100. K. Takeda, M. Nakamoto, H. Hirakata, M. Baba, M. Kubo, and M. Fujishima Disadvantage of long-term CAPD for preserving cardiac performance: an echocardiographic study Am J Kidney Dis 32 3 1998 482 487 (Pubitemid 28411223)
101. A.Y. Wang, J. Sanderson, and M.M. Sea Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis Am J Clin Nutr 77 4 2003 834 841
102. C.J. Konings, J.P. Kooman, and M. Schonck Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study Nephrol Dial Transplant 18 4 2003 797 803 (Pubitemid 36432264)
103. G. Enia, F. Mallamaci, and F.A. Benedetto Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients Nephrol Dial Transplant 16 7 2001 1459 1464 (Pubitemid 32640604)
104. C.J. Konings, J.P. Kooman, and M. Schonck Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study Kidney Int 63 4 2003 1556 1563 (Pubitemid 36350022)
105. S.J. Davies, G. Woodrow, and K. Donovan Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial J Am Soc Nephrol 14 9 2003 2338 2344 (Pubitemid 37052381)
106. 3 with cardiovascular function II. Direct and indirect effects Am J Physiol 253 6, pt 1 1987 E675 E683
107. 3 and cardiovascular function in rats J Clin Invest 79 6 1987 1706 1712 (Pubitemid 17117277)
108. 3 Endocr Rev 10 3 1989 351 365 (Pubitemid 19223066)
109. 3 with cardiovascular function III. Effects on physical and morphological properties Am J Physiol 258 1, pt 1 1990 E134 E142
110. A.Y. Wang, C.W. Lam, and J.E. Sanderson Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study Am J Clin Nutr 87 6 2008 1631 1638 (Pubitemid 351872624)
111. R.J. McGonigle, M.B. Fowler, A.B. Timmis, M.J. Weston, and V. Parsons Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone Nephron 36 2 1984 94 100 (Pubitemid 14212640)
112. 3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes J Clin Invest 97 7 1996 1577 1588 (Pubitemid 26105467)
113. N. Bodyak, J.C. Ayus, and S. Achinger Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals Proc Natl Acad Sci U S A 104 43 2007 16810 16815 (Pubitemid 350210947)
114. Y.C. Li, J. Kong, M. Wei, Z.F. Chen, S.Q. Liu, and L.P. Cao 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system J Clin Invest 110 2 2002 229 238 (Pubitemid 34787360)
115. C.W. Park, Y.S. Oh, and Y.S. Shin Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism Am J Kidney Dis 33 1 1999 73 81
116. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, and J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 25 2003 3133 3140 (Pubitemid 36793081)
117. D.L. Mann, J.J. McMurray, and M. Packer Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 13 2004 1594 1602 (Pubitemid 38451714)
118. N.F. Kelland, and D.J. Webb Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med (Maywood) 231 6 2006 696 699 (Pubitemid 43845511)
119. M. Packer, R.M. Califf, and M.A. Konstam Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 8 2002 920 926 (Pubitemid 34925324)
120. T. Reilly, and M.R. Schork Vasopressin antagonists: pharmacotherapy for the treatment of heart failure Ann Pharmacother 44 4 2010 680 687
121. H. Khan, M. Metra, and J.E. Blair Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 14 4 2009 277 287
122. S.J. Shah, J.E. Blair, and G.S. Filippatos Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial Am Heart J 157 6 2009 1035 1041
123. Y. Sata, and H. Krum The future of pharmacological therapy for heart failure Circ J 74 5 2010 809 817